PMID- 14524738
OWN - NLM
STAT- MEDLINE
DCOM- 20040217
LR  - 20181113
IS  - 0012-6667 (Print)
IS  - 0012-6667 (Linking)
VI  - 63
IP  - 21
DP  - 2003
TI  - Bemiparin: a review of its use in the prevention of venous thromboembolism and 
      treatment of deep vein thrombosis.
PG  - 2357-77
AB  - Bemiparin (bemiparin sodium; Hibor, Ivor, Zibor, Badyket) is a low molecular 
      weight heparin (LMWH) with a lower mean molecular weight (3600 D) and a higher 
      anti-Xa/IIa ratio (8:1) than other LMWHs. Bemiparin was effective as 
      thromboprophylaxis in surgical patients in well controlled clinical trials. No 
      cases of venous thromboembolism (VTE) were reported in low- to moderate-risk 
      patients receiving prophylaxis with bemiparin 2500 anti-Xa IU/day for 7 days or 
      unfractionated heparin (UFH) 5000 anti-Xa IU twice daily for 7 days. In high-risk 
      patients, bemiparin 3500 anti-Xa IU/day for > or =8 days was more effective than 
      UFH 5000 anti-Xa IU twice daily for > or =8 days in the prevention of VTE in 
      patients undergoing total hip replacement. Postoperative bemiparin 3500 anti-Xa 
      IU/day for 10 days was as effective as enoxaparin 4000 anti-Xa IU/day for 10 days 
      commenced 12 hours before surgery in high-risk patients undergoing total knee 
      replacement. As a short-term treatment for acute established deep vein thrombosis 
      (DVT), bemiparin 5000-10 000 anti-Xa IU/day (dependent on bodyweight) for 7 or 10 
      days was more effective than intravenous UFH (5000 anti-Xa IU bolus followed by 
      30,000 or 40,000 anti-Xa IU/day for 7 days) in reducing thrombus size from 
      baseline. Bemiparin 3500 anti-Xa IU/day was also as effective as oral warfarin 
      (10 mg/day for the first 3 days, then adjusted to achieve an international 
      normalised ratio between 2 and 3) for the long-term (12 weeks) treatment of DVT, 
      although data are limited. Subcutaneous bemiparin was generally well tolerated. 
      The most commonly reported adverse events in clinical trials were postoperative 
      bleeding complications (similar incidence to that with UFH or enoxaparin in 
      high-risk patients, lower incidence in low- to moderate-risk patients). 
      CONCLUSIONS: Bemiparin is a new LMWH which has shown efficacy in a small number 
      of well controlled trials in the prevention of postoperative VTE in low- to 
      moderate- and high-risk patients and in the treatment of established DVT. It can 
      be initiated pre- or post-operatively, whereas recommendations for other LMWHs in 
      Europe primarily involve preoperative initiation. Additional comparative studies 
      would be beneficial in determining the overall place of bemiparin, particularly 
      with respect to the relative incidence of bleeding complications. In the 
      meantime, available data suggest that bemiparin is an effective and useful 
      addition to the available range of LMWHs for the prevention of VTE and treatment 
      of DVT.
FAU - Chapman, Therese M
AU  - Chapman TM
AD  - Adis International Limited, Auckland, New Zealand. demail@adis.co.nz
FAU - Goa, Karen L
AU  - Goa KL
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - PUE0TO3XDR (bemiparin)
SB  - IM
MH  - Area Under Curve
MH  - Economics, Pharmaceutical
MH  - Heparin, Low-Molecular-Weight/metabolism/pharmacokinetics/*therapeutic use
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Tissue Distribution
MH  - Venous Thrombosis/*drug therapy/prevention & control
RF  - 45
EDAT- 2003/10/04 05:00
MHDA- 2004/02/18 05:00
CRDT- 2003/10/04 05:00
PHST- 2003/10/04 05:00 [pubmed]
PHST- 2004/02/18 05:00 [medline]
PHST- 2003/10/04 05:00 [entrez]
AID - 63219 [pii]
AID - 10.2165/00003495-200363210-00009 [doi]
PST - ppublish
SO  - Drugs. 2003;63(21):2357-77. doi: 10.2165/00003495-200363210-00009.